This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Otolaryngology/ Head & Neck Surgery  • Endocrine Disease of Head & Neck  • Endocrine Diseases  • Thyroid/ Parathyroid Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Where Do We Stand After 50 Years?

David S. Cooper, MD

JAMA. 1998;280:375-376.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hyperthyroidism is a common clinical condition, with an annual incidence of about 1%.¹ Approximately 1 in every 20 women will develop this condition during a lifetime.¹ Most cases are due to Graves disease, with solitary toxic nodules and toxic multinodular goiters being important, although less frequent, causes. The treatment of hyperthyroidism due to Graves disease is still somewhat controversial. In the United States, iodine 131 is the preferred therapy in adults, but antithyroid agents are favored in younger individuals.² In Europe and Japan, antithyroid drugs are recommended more often than ¹³¹I regardless of the patient's age.³ Surgery for hyperthyroidism is used infrequently in any part of the world.^2-3

Since the introduction of ¹³¹I in the early 1940s,⁴ it is likely that millions of patients have been treated.⁵ And yet, despite its ease of administration, lack of significant adverse effects,⁶ and low cost, many physicians are still . . . [Full Text of this Article]

From the Division of Endocrinology, Sinai Hospital of Baltimore, The Johns Hopkins University School of Medicine, Baltimore, Md. Dr Cooper is Contributing Editor, JAMA.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Cancer Mortality Following Treatment for Adult Hyperthyroidism
Elaine Ron, Michele Morin Doody, David V. Becker, A. Bertrand Brill, Rochelle E. Curtis, Marlene B. Goldman, Benjamin S. H. Harris III, Daniel A. Hoffman, William M. McConahey, Harry R. Maxon, Susan Preston-Martin, M. Ellen Warshauer, F. Lennie Wong, John D. Boice, Jr, and for the Cooperative Thyrotoxicosis Therapy Follow-up Study Group
JAMA. 1998;280(4):347-355.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radioiodine Therapy for Multinodular Toxic Goiter
Nygaard et al.
Arch Intern Med 1999;159:1364-1368.
ABSTRACT | FULL TEXT  

Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial • Commentary: Concurrent economic evaluations are rare but should be standard practice
Roberts et al.
BMJ 1998;317:911-916.
ABSTRACT | FULL TEXT  

Long-Term Consequences of I-131 Are Minor
JWatch General 1998;1998:5-5.
FULL TEXT